AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that its Board of Directors, after consultation with its legal and financial advisors, has unanimously determined that the previously disclosed proposal by MSMB Capital is not reasonably expected to result in a superior offer to the merger with Allos Therapeutics, Inc. Therefore, the AMAG Board of Directors unanimously opposes MSMB Capital’s proposal and reaffirms its prior determination that the merger agreement with Allos Therapeutics, Inc. and the merger contemplated thereby are advisable and fair to, and in the best interests of, AMAG and its stockholders.
Read more at: http://crwewallstreet.com/?p=20965